Famicord Ag · XETR:V3V
Famicord — Investor Presentation (November 2024)
17 slides from Famicord's investor presentation, Nov 26, 2024
Slide 1: Famicord today and tomorrow
Famicord today and tomorrow FRANKFURT, 26 november 2024
Slide 2: Empowered purpose, mission and vision
Empowered purpose, mission and vision Vision Mission Purpose Identity We envision a future where Our mission is to empower We preserve cells for Vita 34, as the first and leading cell banking and advanced families with personalized personalized therapies European provider in cell banking, cell thera
Slide 3: FamiCord in Europe and beyond
FamiCord in europe and beyond • No. 1 in Europe • No. 2 in the world (ex-China) • ~50% of market share in Europe • > 1 million of samples stored • 13 processing labs • 2 storage labs • 2 CDMO centers • CAR-T dedicated R&D team 3
Slide 4: Market situation
Market situation Strong position indicates obvious growth directions Higer share caused by: Countries • Vita34 better market ~66% of operation Vita34 holds ~66% market share (B2C and B2B), averaged across share in smaller countries countries of presence based on the percentage of samples sent • Coun
Slide 5: Family banking penetration
Family banking penetration • European penetration is below 2%, with potential to grow at least to US levels (3-4%). • The highest penetration in Europe continues to be in Portugal, Hungary and Romania. • Spain should grow due to the ruling of the Highest Court enabling collections for all Spanish ci
Slide 6: Europe: on-going market consolidation
Europe: ON-GOING market consolidation 15 YEARS AGO 5 YEARS AGO TODAY TOMORROW ~150 <100 ~60 40 PLAYERS PLAYERS PLAYERS PLAYERS • Some players have own lab while the others outsource the services. • Percentage of companies having own lab is going up, so most of those stopping the activity are those n
Slide 7: Position against key competitors
Position against key competitors Vita34 Competitor 1 Competitor 2 Competitor 3 clients base • Leader in all key categories so market growth 5 is a priority. 4 non-banking • Key factors to focus on: new clients revenue 3 2 • sales excellence to increase margins 1 • cash generation 0 • fix-cost optimi
Slide 8: Industry hit by three black swans
Industry hit by three black swans Each of them separately could be considered as a black swan for the industry ↘ Ex-leader bankruptcy in 2019 ↘ COVID 2020 Live births EU-27 4.500.000 • Biggest impact: trust toward the industry was hit • Off-line channels were hit dramatically. The service of stem-ce
Slide 9: Family stem cell banking sector SWOT analysis
Family stem cell banking sector SWOT analysis for Europe Strenghts Oportunities • Potential of growing current service penetration • Development of stem cell therapies • Solid base of existing clients being advocates of the service • Closer partnership with HCP organizations and hospitals • Market w
Slide 10: More stem cell therapies trigger more interest in cell banking
More stem cell therapies trigger more interest in cell banking Strenghts Oportunities • Stem cell therapies are overall considered very safe • Clinical trials advancing with good results • Close to 1000 clinical trials with stem cells going-on • Developments in science in China and US • Solution for
Slide 11: It works!
4¢FamiCord CY, It works!
Slide 12: It works! Stem cells are important to develop new therapies
It works! Stem cells are important to develop new therapies Number of active cell therapies in clinical trials Cord blood recommended 1600 in treatment of cerebral 1400 palsy at children 1200 1000 800 1487 600 1178 910 400 200 0 Stem Cell Allogeneic Cell Autologous Therapies Therapies Cell Therapies
Slide 13: New medical data supporting banking are available
New medical data supporting banking are available • Technology eliminating key issue of small cord blood volume collections approved by FDA. • Next step is EMA approval. • Alternative expansion technology projects Plenty of data confirming usefulness of CB stored many years ago are are also advancin
Slide 14: Roll-out of placenta banking
ROLL - OUT of placenta BANKING Placenta is naturally considered as „source of life” LAUNCHED MARKET EXPERIENCE BUSINESS EFFECTS EXPECTED • We have an excellent experience from Switzerland as well as • We have an excellent experience from Switzerland as well as from from GCC in terms of service accep
Slide 15: Cash revenues from clients' base
Cash revenues from clients’ base Gradual growth of revenue stream from already stored samples Expiring existing prepayment contracts 2023-2027 Annually paying Prolongations in Existing clients buying 14 000 13 349 clients prepayments extra services 13 000 12 422 12 423 12 545 12 000 Cash revenues fr
Slide 16: Thank you for your attention
Thank you for your attention Contact • Jakub Baran (CEO) jakub.baran@vita34.de Perlickstraße 5, 04103 Leipzig Tel. +49 341 48792 7574 • Thomas Pfaadt (CFO) thomas.pfaadt@vita34.de Fax +49 341 48792 39 • Ingo Middelmenne (IRO) ingo.middelmenne@vita34.de www.vita34.de
Slide 17: Thank you for your attention
Thank you for your attention Contact • Jakub Baran (CEO) jakub.baran@vita34.de Perlickstraße 5, 04103 Leipzig Tel. +49 341 48792 7574 • Thomas Pfaadt (CFO) thomas.pfaadt@vita34.de Fax +49 341 48792 39 • Ingo Middelmenne (IRO) ingo.middelmenne@vita34.de www.vita34.de